Skip to main content
. 2022 Jul 1;4(1):vdac102. doi: 10.1093/noajnl/vdac102

Table 2.

Imaging and molecular characteristics in 33 patients diagnosed with butterfly glioblastoma between 01/01/2007 and 31/12/2014

MRI characteristics
 Corpus callosum affectiona
  Rostrum/genu 21 (63.6%)
  Body 25 (75.8%)
  Splenium 14 (42.4%)
 Tumor distribution
  Left skewed 13 (39.4%)
  Right skewed 13 (39.4%)
  Symmetric 7 (21.2%)
 Tumor volumes
  T1-weighted contrast-enhanced MRI (cm3) 41 (26–73)
  T2-weighted/FLAIR MRI (cm3) 137 (83–229)
  Ratio T2/FLAIR:T1 volumes 3.2 (2.4–4.4)
 Hypothalamus involvement 11 (33.3%)
 Basal ganglia involvement 14 (42.4%)
 Blood vessel affection 20 (60.6%)
 Necrosis 28 (84.8%)
 Flow void 23 (69.7%)
 Mass effectb 16 (48.5%)
Molecular characteristics (n = 11)c
 MGMT promoter methylation status
  Inconclusive 2 (18.2%)
  Methylated 2 (18.2%)
  Unmethylated 7 (63.6%)
 BRAF mutational status
  BRAF V600E mutation 0 (0.0%)
  BRAF V600E wild type 11 (100.0%)

Tumor volumes and T2/FLAIR:T1 ratio presented as median (IQR), all others as absolute numbers (%). Tumor volumes defined as contrast enhancement and necrosis in T1-weighted MRI and tumor associated non-enhancing hyperintense lesions in T2-weighted/FLAIR MRI.

MRI, magnetic resonance imaging; FLAIR, fluid attenuated inversion recovery; cm3, cubic centimeters; MGMT, O(6)-methylguanine-DNA methyltransferase.

aSum exceeding 100% due to the affection of multiple regions in several patients.

bDefined as midline shift ≥ 1 mm.

cPresented as absolute numbers and % of patients with histological sample available for re-evaluation and molecular analyses.